• Profile
Close

Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose–effect

Radiotherapy & Oncology Aug 24, 2017

Cozzarini C, et al. – The unknown dose–effect relationship for late patient–reported urinary incontinence (LPRUI) was examined. For prostate cancer (PCa), LPRUI after radiotherapy (RT) dramatically depended on 2 Gy equivalent dose (EQD2) and few clinical factors. A consistency was observed between results and a larger than expected impact of moderate hypo–fractionation on the risk of LPRUI. As expected, a link was noted between baseline symptoms, as captured by ICIQ–SF, and an increased risk of LPRUI.

Methods

  • The multi-centric study DUE01 incorporated patients.
  • Researchers gathered clinical and dosimetry data including the prescribed 2 Gy equivalent dose (EQD2).
  • Via the ICIQ-SF questionnaire filled in by the patients at RT start/end and therefore every 6 months, LPRUI was evaluated.
  • Conventional (74–80 Gy, 1.8–2 Gy/fr) or moderately hypo-fractionated RT (65–75.2 Gy, 2.2–2.7 Gy/fr) in 5 fractions/week with intensity-modulated radiotherapy had been given to patients.
  • They considered six different end-points of 3-year LPRUI, including or not patient’s perception (respectively, subjective and objective end-points).
  • For each end-point, multivariable logistic models were developed.

Results

  • They examined data of 298 patients.
  • 5.1% was the incidence of the most severe end-point (ICIQ-SF>12).
  • In addition, EQD2 calculated with alpha–beta=0.8 Gy showed the best performance in fitting data: the risk of LPRUI markedly increased for EQD2>80 Gy.
  • The clinical factors more significantly predictive of LPRUI were previous abdominal/pelvic surgery and previous TURP.
  • Confirmed by bootstrap-based internal validation, models showed excellent performances in terms of goodness-of-fit and calibration.
  • Baseline symptoms were a major predictor for 5 out of six end-points when included in the analyses.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay